替比夫定优化方案与恩替卡韦治疗HBeAg阳性慢性乙型肝炎的药物经济学评价

被引：10

作者：

叶晓光

欧阳仁杰

机构：

[1] 广州医科大学附属第二医院感染科

来源：

实用医学杂志 | 2015年 / 31卷 / 07期

关键词：

肝炎,乙型,慢性; 药物经济学; Markov模型; 成本效果;

D O I：

暂无

中图分类号：

R512.62 [];

学科分类号：

摘要：

目的:对替比夫定优化方案与恩替卡韦方案治疗HBe Ag阳性慢性乙型肝炎进行药物经济学评价。方法:根据慢性乙型肝炎进展规律,构建含多个健康状态的Markov模型,以替比夫定单药方案作基准,估计替比夫定优化方案与恩替卡韦方案治疗HBe Ag阳性慢性乙型肝炎患者的长期效果和医疗费用,并进行增量分析。结果:使用恩替卡韦方案使HBe Ag阳性慢性乙型肝炎患者获得35.95年的期望生存年和22.94个质量调整生命年,其总费用为349 279.27元,每延长1个质量调整生命年多需的医疗费用为15 225.77元。使用替比夫定优化方案获得了长于恩替卡韦方案的36.11年的期望生存年和23.08个质量调整生命年,其总费用为348 863.62元,每延长1个质量调整生命年多需的医疗费用为15 115.41元,低于恩替卡韦方案的15 225.77元。结论:使用替比夫定优化方案相比恩替卡韦方案具有略优的成本效果,可以作为临床上HBe Ag阳性慢性乙型肝炎抗病毒治疗的较优选择。

引用

页码：1053 / 1057

页数：5

共 11 条

[1]

中国统计年鉴.[Z].郑京平总编.中国统计出版社.2005,

[2]

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection [J].

Papatheodoridis, George ;

Buti, Maria ;

Cornberg, Markus ;

Janssen, Harry ;

Mutimer, David ;

Pol, Stanislas ;

Raimondo, Giovanni .

JOURNAL OF HEPATOLOGY, 2012, 57 (01) :167-185

[3]

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update [J].

Liaw, Yun-Fan ;

Kao, Jia-Horng ;

Piratvisuth, Teerha ;

Chan, Henry Lik Yuen ;

Chien, Rong-Nan ;

Liu, Chun-Jen ;

Gane, Ed ;

Locarnini, Stephen ;

Lim, Seng-Gee ;

Han, Kwang-Hyub ;

Amarapurkar, Deepak ;

Cooksley, Graham ;

Jafri, Wasim ;

Mohamed, Rosmawati ;

Hou, Jin-Lin ;

Chuang, Wan-Long ;

Lesmana, Laurentius A. ;

Sollano, Jose D. ;

Suh, Dong-Jin ;

Omata, Masao .

HEPATOLOGY INTERNATIONAL, 2012, 6 (03) :531-561

[4]

Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis [J].

Wu, Bin ;

Li, Te ;

Chen, Huafeng ;

Shen, Jinfang .

VALUE IN HEALTH, 2010, 13 (05) :592-600

[5]

Management of chronic hepatitis B: experience from China.[J].J.Sun;J. L.Hou.Journal of Viral Hepatitis.2010,

[6]

2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B [J].

Liaw, Yun-Fan ;

Gane, Edward ;

Leung, Nancy ;

Zeuzem, Stefan ;

Wang, Yuming ;

Lai, Ching Lung ;

Heathcote, E. Jenny ;

Manns, Michael ;

Bzowej, Natalie ;

Niu, Junqi ;

Han, Steven-Huy ;

Hwang, Seong Gyu ;

Cakaloglu, Yilmaz ;

Tong, Myron J. ;

Papatheodoridis, George ;

Chen, Yagang ;

Brown, Nathaniel A. ;

Albanis, Efsevia ;

Galil, Karin ;

Naoumov, Nikolai V. .

GASTROENTEROLOGY, 2009, 136 (02) :486-495

[7]

Baseline characteristics and early on-treatment response predict the outcomes of 2<ce:hsp sp="0.25"/>years of telbivudine treatment of chronic hepatitis B.[J].Stefan Zeuzem;Edward Gane;Yun-Fan Liaw;Seng G. Lim;Adrian DiBisceglie;Maria Buti;Anuchit Chutaputti;Jens Rasenack;Jinlin Hou;Christopher O’Brien;Tuan T. Nguyen;Jidong Jia;Thierry Poynard;Bruce Belanger;Weibin Bao;Nikolai V. Naoumov.Journal of Hepatology.2009, 1

[8]

The impact of chronic hepatitis B on quality of life: A multinational study of utilities from infected and uninfected persons [J].